AEGON ASSET MANAGEMENT UK Plc raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 113,223 shares of the company’s stock after buying an additional 5,999 shares during the period. AEGON ASSET MANAGEMENT UK Plc’s holdings in Johnson & Johnson were worth $20,129,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in JNJ. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter worth approximately $4,172,929,000. BlackRock Inc. raised its stake in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares during the last quarter. GQG Partners LLC raised its stake in shares of Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock worth $676,375,000 after purchasing an additional 3,627,424 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after purchasing an additional 3,358,478 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares during the last quarter. Institutional investors own 68.59% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several analyst reports. SVB Leerink lowered their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. UBS Group decreased their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Wells Fargo & Company increased their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Finally, Daiwa Capital Markets started coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $189.78.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the company earned $2.48 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.7 EPS for the current year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.77%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is 65.79%.
Johnson & Johnson announced that its board has initiated a stock buyback plan on Wednesday, September 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to buy up to 1.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.